BioCentury | Oct 12, 2018
Clinical News

Checkpoint's CK-101 leads to 75% ORR in NSCLC subgroup of Phase I/II

...which has exclusive rights to develop and commercialize CK-101 outside of undisclosed Asian countries from Suzhou NeuPharma Co. Ltd....
...deal. Checkpoint Therapeutics Inc. (NASDAQ:CKPT), New York, N.Y. Fortress Biotech Inc. (NASDAQ:FBIO), New York, N.Y. Suzhou NeuPharma Co. Ltd....
...PFS) Status: Phase I/II data Milestone: Start Phase III (2019) Jennie Walters CK-101, RX518 Checkpoint Therapeutics Inc. Fortress Biotech Inc. Suzhou NeuPharma Co. Ltd. Epidermal...
BioCentury | Apr 11, 2017
Distillery Therapeutics

Cancer

...glioma. Phoenix Biotechnology Inc. has oleandrin (PBI-05204) in Phase I testing to treat solid tumors. Suzhou NeuPharma Co. Ltd....
BioCentury | Aug 15, 2016
Clinical News

CK-101: Phase I/II start

...deal. Checkpoint Therapeutics Inc. , New York, N.Y. Fortress Biotech Inc. (NASDAQ:FBIO), New York, N.Y. Suzhou NeuPharma Co. Ltd....
BioCentury | Jun 29, 2015
Clinical News

RX108: Phase I started

...Suzhou NeuPharma began an open-label, Australian Phase I trial of Rx10 8. Suzhou NeuPharma Co. Ltd. , Suzhou, China...
BioCentury | Apr 13, 2015
Company News

Suzhou NeuPharma, Coronado Biosciences deal

...undisclosed EGFR mutations. Coronado declined to disclose further details, and NeuPharma could not be reached. Suzhou NeuPharma Co. Ltd....
Items per page:
1 - 5 of 5
BioCentury | Oct 12, 2018
Clinical News

Checkpoint's CK-101 leads to 75% ORR in NSCLC subgroup of Phase I/II

...which has exclusive rights to develop and commercialize CK-101 outside of undisclosed Asian countries from Suzhou NeuPharma Co. Ltd....
...deal. Checkpoint Therapeutics Inc. (NASDAQ:CKPT), New York, N.Y. Fortress Biotech Inc. (NASDAQ:FBIO), New York, N.Y. Suzhou NeuPharma Co. Ltd....
...PFS) Status: Phase I/II data Milestone: Start Phase III (2019) Jennie Walters CK-101, RX518 Checkpoint Therapeutics Inc. Fortress Biotech Inc. Suzhou NeuPharma Co. Ltd. Epidermal...
BioCentury | Apr 11, 2017
Distillery Therapeutics

Cancer

...glioma. Phoenix Biotechnology Inc. has oleandrin (PBI-05204) in Phase I testing to treat solid tumors. Suzhou NeuPharma Co. Ltd....
BioCentury | Aug 15, 2016
Clinical News

CK-101: Phase I/II start

...deal. Checkpoint Therapeutics Inc. , New York, N.Y. Fortress Biotech Inc. (NASDAQ:FBIO), New York, N.Y. Suzhou NeuPharma Co. Ltd....
BioCentury | Jun 29, 2015
Clinical News

RX108: Phase I started

...Suzhou NeuPharma began an open-label, Australian Phase I trial of Rx10 8. Suzhou NeuPharma Co. Ltd. , Suzhou, China...
BioCentury | Apr 13, 2015
Company News

Suzhou NeuPharma, Coronado Biosciences deal

...undisclosed EGFR mutations. Coronado declined to disclose further details, and NeuPharma could not be reached. Suzhou NeuPharma Co. Ltd....
Items per page:
1 - 5 of 5